Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire

23 May 2025

Abstract excerpt

While Chimeric Antigen Receptor (CAR) T cell therapy may result in durable remissions in recurrent large B cell lymphoma, persistence is limited and the mechanisms underlying long-term response are not fully elucidated. Using longitudinal single-cell immunoprofiling, here we compare the immune landscape in durable remission versus early relapse patients following CD19 CAR T cell infusion in the NCT02348216...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40410132
DOI: 10.1038/s41467-025-59904-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoirePMID 40410132Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B-cell lymphomaSemantic proximity Read ↗

Decade-long remissions of leukemia sustained by the persistence of activated CD4 <sup>+</sup> CAR T-cellsSemantic proximity Read ↗

Functional diversification and dynamics of CAR-T cells in patients with B-ALLSemantic proximity Read ↗

Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphomaSemantic proximity Read ↗

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cellsSemantic proximity Read ↗

CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignanciesSemantic proximity Read ↗

Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell TherapySemantic proximity Read ↗

Two-Stage CD8 <sup>+</sup> CAR T-Cell Differentiation in Patients with Large B-Cell LymphomaSemantic proximity Read ↗

Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity Read ↗

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.Semantic proximity Read ↗

CAR+ and CAR- T cells differentiate into an NK-like subset that is associated with increased inflammatory cytokines following infusionSemantic proximity Read ↗

Single-cell antigen-specific activation landscape of CAR T infusion product identifies determinants of CD19 positive relapse in patients with ALLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.